1-propyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid | 147796-05-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 1-propyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid
• 英文别名: 1-propyl-1,2,3,4-tetrahydronorharman-3-carboxylic acid；1-propyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-ium-3-carboxylate
• CAS: 147796-05-2
• 化学式: C₁₅H₁₈N₂O₂
• 分子量: 258.32
• InChiKey: MCRTVLJNXKXHBA-UHFFFAOYSA-N

物化性质

• 溶解度：
  37.3 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  65.1
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1-propyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid 在 盐酸 、 potassium dichromate 、 溶剂黄146 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 0.33h， 生成 1-propyl-9H-pyrido[3,4-b]indole
  参考文献：
  名称：

  Carbazole and carboline derivatives, and preparation and therapeutic applications thereof

  摘要：

  通式（I）的化合物：其中A、R1和R2的定义如下，在治疗或预防包括癌症在内的增殖性疾病中是有用的。

  公开号：

  EP2455378A1
• 作为产物：
  描述：

  正丁醛 、 L-色氨酸 以 盐酸 为溶剂， 反应 72.0h， 以to give 3.41 g of 1-propyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid的产率得到1-propyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid
  参考文献：
  名称：

  CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF

  摘要：

  通式(I)的化合物，其中A，Y，R1和R2的定义见此处，可用于治疗或预防增生性疾病，包括癌症或传染性或寄生性疾病。

  公开号：

  US20130274258A1

文献信息

• [EN] CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF<br/>[FR] DÉRIVÉS DE CARBAZOLE ET DE CARBOLINE, ET LEUR PRÉPARATION ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：PHILIP MORRIS PROD

  公开号：WO2012059232A1

  公开（公告）日：2012-05-10

  Compounds of general formula (I), wherein A, Y, R1 and R2 are defined herein are useful in the treatment or prevention of proliferative diseases including cancer or infectious or parasitic diseases.

  通式（I）中的化合物，其中A、Y、R1和R2的定义如下，在治疗或预防包括癌症或传染性或寄生虫病在内的增殖性疾病方面是有用的。
• Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo
  申请人：Wu Jialin

  公开号：US20090227619A1

  公开（公告）日：2009-09-10

  This invention relates to compounds of general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumour activity and lower nervous system toxicity by structurally modification of the parent structure of β-carboline of harmines at position 1, 2, 3, 7 and 9. The compounds of the present invention can be prepared easily with high yield. They can be used in manufacture of a variety of antitumour medicines and medicines used in treatment of tumour diseases in combination of light or radiation therapy.

  本发明涉及一般式（I）的化合物，其中R1、R2、R3、R4和R5如规范中所定义；用于它们的制备的中间体，制备方法和使用。本发明通过在β-噻吩类似物的母体结构的1、2、3、7和9位进行结构修饰，产生具有增强抗肿瘤活性和较低神经系统毒性的新的harmine衍生物。本发明的化合物可以轻松高产制备。它们可以用于制造各种抗肿瘤药物和用于结合光或放射治疗治疗肿瘤疾病的药物。
• METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS
  申请人：Almstead Neil

  公开号：US20120202763A1

  公开（公告）日：2012-08-09

  Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

  本文介绍了选择性抑制人类血管内皮生长因子（VEGF）病理性产生的化合物以及包含这些化合物的组合物。本文还介绍了抑制病毒复制或病毒RNA或DNA或病毒蛋白质产生的化合物以及包含这些化合物的组合物。同时，本文还介绍了使用这些化合物减少VEGF的方法以及使用这些化合物治疗癌症和非肿瘤性疾病的方法。本文还介绍了使用这些化合物抑制病毒复制或病毒RNA或DNA或病毒蛋白质产生的方法以及使用这些化合物治疗病毒感染的方法。这些化合物可以作为单一治疗剂或与一个或多个其他治疗剂联合使用，用于治疗需要这些治疗的人类。
• Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof
  申请人：Wu Jialin

  公开号：US08772311B2

  公开（公告）日：2014-07-08

  This invention relates to compounds of general formula (I), wherein R1, R2, R3, R4 and R5 are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumor activity and lower nervous system toxicity by structurally modification of the parent structure of β-carboline of harmines at position 1, 2, 3, 7 and 9. The compounds of the present invention can be prepared easily with high yield. They can be used in manufacture of a variety of antitumor medicines and medicines used in treatment of tumor diseases in combination of light or radiation therapy.

  本发明涉及通式（I）的化合物，其中R1，R2，R3，R4和R5如规范中所定义；用于其制备的中间体，制备过程以及其用途。本发明通过在β-咔啉毒素的母体结构的1、2、3、7和9位进行结构修饰，产生具有增强的抗肿瘤活性和较低的神经系统毒性的新的哈曼衍生物。本发明的化合物可以轻松地高产制备。它们可以用于制造各种抗肿瘤药物和联合光或放射治疗用于治疗肿瘤疾病的药物。
• β-Carbolines as specific inhibitors of cyclin-Dependent kinases
  作者：Yongcheng Song、Jian Wang、Su Fern Teng、Djohan Kesuma、Yu Deng、Jinao Duan、Jerry H. Wang、Robert Zhong Qi、Mui Mui Sim

  DOI：10.1016/s0960-894x(02)00094-x

  日期：2002.4

  Harmine (3), 7-fluoro-1-methyl beta-carboline (35) and 1-(5-methyl-imidazol-4-yl) beta-carboline (41) were potent and specific inhibitors of cyclin-dependent kinases. The degree of aromaticity of the tricyclic ring and the positioning of substituents are important for inhibitory activity. While most beta-carbolines inhibited CDK2 and CDK5 to the same extent. selective inhibition against CDK2 was observed in 1-(2-chlorophenyl)- (12), 1-(2-fluorophenyl)- (15), and 1-(2-chloro-5-nitrophenyl)- (28) beta-carbolines. (C) 2002 Elsevier Science Ltd. All rights reserved.